Intravenous Immunoglobulin Controls Th17 Cell-Mediated Osteoclastogenesis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The purpose of this study was to determine the regulatory role of intravenous Ig (IVIg) in Th17 cytokine–induced RANK ligand (RANKL) expression and osteoclast (OC) differentiation from OC precursors (pre-OC). Human CD14+ monocytes were isolated and stimulated by Th17 cytokines (IL-17, IL-21, and IL-22) and RANKL expression was investigated using a real-time PCR. CD14+ monocytes were incubated with RANKL, Th17 cytokines, and M-CSF, with/without IVIg, and OC differentiation was determined by counting tartrate-resistant acid phosphatase-positive multinucleated cells. OC differentiation was investigated after monocytes were cocultured with Th17 cells in the presence of IVIg. Th17 cell differentiation was determined using enzyme-linked immunosorbent assay and flow cytometry after CD4+ T cells were cultured with IVIg under Th17 condition. Th17 cytokines stimulated monocytes to express RANKL and IVIg suppressed the Th17 cytokine-induced RANKL expression. OCs were differentiated when pre-OC were cocultured with RANKL or Th17 cytokines and IVIg reduced the osteoclastogenesis. IVIg also decreased osteoclastogenesis when pre-OC were cocultured with Th17 cells. IVIg decreased both Th17 and Th1 cell differentiation while it did not affect Treg cell differentiation. In summary, IVIg inhibited Th17 cytokine-induced RANKL expression and OC differentiation. IVIg reduced osteoclastogenesis when monocytes were cocultured with Th17 cells. IVIg also reduced Th17 polarization. IVIg could be a new therapeutic option for Th17 cell–mediated osteoclastogenesis.
Abstract
The purpose of this study was to determine the regulatory role of intravenous Ig (IVIg) in Th17 cytokine–induced RANK ligand (RANKL) expression and osteoclast (OC) differentiation from OC precursors (pre-OC). Human CD14+ monocytes were isolated and stimulated by Th17 cytokines (IL-17, IL-21, and IL-22) and RANKL expression was investigated using a real-time PCR. CD14+ monocytes were incubated with RANKL, Th17 cytokines, and M-CSF, with/without IVIg, and OC differentiation was determined by counting tartrate-resistant acid phosphatase-positive multinucleated cells. OC differentiation was investigated after monocytes were cocultured with Th17 cells in the presence of IVIg. Th17 cell differentiation was determined using enzyme-linked immunosorbent assay and flow cytometry after CD4+ T cells were cultured with IVIg under Th17 condition. Th17 cytokines stimulated monocytes to express RANKL and IVIg suppressed the Th17 cytokine-induced RANKL expression. OCs were differentiated when pre-OC were cocultured with RANKL or Th17 cytokines and IVIg reduced the osteoclastogenesis. IVIg also decreased osteoclastogenesis when pre-OC were cocultured with Th17 cells. IVIg decreased both Th17 and Th1 cell differentiation while it did not affect Treg cell differentiation. In summary, IVIg inhibited Th17 cytokine-induced RANKL expression and OC differentiation. IVIg reduced osteoclastogenesis when monocytes were cocultured with Th17 cells. IVIg also reduced Th17 polarization. IVIg could be a new therapeutic option for Th17 cell–mediated osteoclastogenesis.
참고문헌 (26)
- Lee JH, "Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal", Mol Pharmacol, 77, pp.17~25 (2010)
- Qi B, "Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice", Sci Rep, 4, pp.7158~ (2014)
- Gravallese EM, "Bone destruction in arthritis", Ann Rheum Dis, 61(Suppl 2), pp.ii84~ii86 (2002)
- Pöllinger B, "Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans", J Immunol, 186, pp.2602~2612 (2011)
- Kim KW, "Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts", Arthritis Rheum, 64, pp.1015~1023 (2012)
- Kim KW, "Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis", Am J Pathol, 185, pp.3011~3024 (2015)
- Bayry J, "Intravenous immunoglobulin therapy in rheumatic diseases", Nat Rev Rheumatol, 7, pp.349~359 (2011)
- Jia S, "The T helper type 17", regulatory T cell imbalance in patients with acute Kawasaki disease, 2010, pp.162, 131~137
- Benoist C, "A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?", Arthritis Res, 2, pp.90~94 (2000)
- Maddur MS, "Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin", J Allergy Clin Immunol, 127, pp.823~830.e1-e7 (2011)
- Maddur MS, "Comparison of different IVIg preparations on IL-17 production by human Th17 cells", Autoimmun Rev, 10, pp.809~810 (2011)
- ee MJ, "Intravenous immunoglobulin (IVIG)attenuates TNF-induced pathologic bone resorption and suppresses osteoclastogenesis by inducing A20expression", J Cell Physiol, 231, pp.449~458 (2016)
- 김해림, "N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis", The Korean Journal of Internal Medicine, 34(1), pp.210~219 (2019), 대한내과학회[DOI]
- Ganjalikhani Hakemi M, "Optimization of human Th17 cell differentiation in vitro: evaluating different polarizing factors", In Vitro Cell Dev Biol Anim, 47, pp.581~592 (2011)
- Chung BH, "Suppressive effect of 1α,25-dihydroxyvitamin D3 on Th17-immune responses in kidney transplant recipients with tacrolimus-based immunosuppression", Transplantation, 101, pp.1711~1719 (2017)
- Han SH, "Preliminary study of histamine H4 receptor expressed on human CD4+ T cells and its immunomodulatory potency in the IL-17pathway of psoriasis", J Dermatol Sci, 88, pp.29~35 (2017)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Koenders MI, "Secukinumab for rheumatology: development and its potential place in therapy", Drug Des Devel Ther, 10, pp.2069~2080 (2016)
- Katz-Agranov N, "The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis", Autoimmun Rev, 14, pp.651~658 (2015)
- Lee SY, "Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17and Treg cells in an interleukin-10-dependent manner", Arthritis Rheumatol, 66, pp.1768~1778 (2014)
- Delgoffe GM, "The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2", Nat Immunol, 12, pp.295~303 (2011)
- Hoerning A, "Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity", Transplantation, 99, pp.210~219 (2015)
- Yang CS, "Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin", 70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages, 2006, pp.8, 1158~1171
- Ellis GI, "Generation of induced regulatory T cells from primary human naïve and memory T cells", J Vis Exp, pp.3738~ (2012)
- Reneer MC, "Peripherally induced human regulatory T cells uncouple Kv1.3 activation from TCR-associated signaling", Eur J Immunol, 41, pp.3170~3175 (2011)
- Saxena A, "Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent", Arthritis Rheum, 63, pp.1465~1466 (2011)